{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:49:43Z","timestamp":1758397783223,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford Clarendon Foundation"},{"name":"Abbott contracted IQVIA for the conducting of this study"},{"name":"Had a contract with Abbott International, as Consultant for scientific projects"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40265-022-01822-z","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T12:34:35Z","timestamp":1674563675000},"page":"249-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-0042","authenticated-orcid":false,"given":"Junqing","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Brash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigdem","family":"Turkmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Seager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-6346","authenticated-orcid":false,"given":"Daniel","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1086","volume":"368","author":"M Day","year":"2020","unstructured":"Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368: m1086. https:\/\/doi.org\/10.1136\/bmj.m1086.","journal-title":"BMJ"},{"key":"1822_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1555","volume":"369","author":"I Torjesen","year":"2020","unstructured":"Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ. 2020;369: m1555. https:\/\/doi.org\/10.1136\/bmj.m1555.","journal-title":"BMJ"},{"key":"1822_CR3","unstructured":"Roy S. Coronavirus: alerte sur l\u2019ibuprof\u00e8ne et autres anti-inflammatoires. Le Figaro. Updated March 14, 2020. 2022. https:\/\/www.lefigaro.fr\/sciences\/coronavirus-alerte-sur-l-ibuprofene-et-autres-anti-inflammatoires-20200314. Accessed 28 Feb 2022."},{"key":"1822_CR4","doi-asserted-by":"publisher","unstructured":"Fernandez-Gutierrez B, Leon L, Madrid A, et al. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis. 2021. doi: https:\/\/doi.org\/10.1177\/1759720X20962692.","DOI":"10.1177\/1759720X20962692"},{"issue":"4","key":"1822_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4): e21. https:\/\/doi.org\/10.1016\/S2213-2600(20)30116-8.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1822_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8. https:\/\/doi.org\/10.1016\/j.cell.2020.02.052.","journal-title":"Cell"},{"issue":"5","key":"1822_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785\u201391. https:\/\/doi.org\/10.1136\/ard.2010.128637.","journal-title":"Ann Rheum Dis"},{"key":"1822_CR8","unstructured":"European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020. https:\/\/www.ema.europa.eu\/en\/news\/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. Accessed 5 Jul 2020 ."},{"key":"1822_CR9","doi-asserted-by":"publisher","unstructured":"Monti S, Montecucco C. Non-steroidal anti-inflammatory treatment during COVID-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al. Ann Rheum Dis. 2021;80(2):e13.https:\/\/doi.org\/10.1136\/annrheumdis-2020-217638","DOI":"10.1136\/annrheumdis-2020-217638"},{"key":"1822_CR10","unstructured":"NICE. Key messages. COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. 2020. https:\/\/www.nice.org.uk\/advice\/es23\/chapter\/Key-messages. Accessed 5 July 2020."},{"issue":"5","key":"1822_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/art.41593","volume":"73","author":"JS Chandan","year":"2021","unstructured":"Chandan JS, Zemedikun DT, Thayakaran R, et al. Nonsteroidal antiinflammatory drugs and susceptibility to COVID-19. Arthritis Rheumatol. 2021;73(5):731\u20139. https:\/\/doi.org\/10.1002\/art.41593.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1822_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/annrheumdis-2020-219517","volume":"80","author":"AY Wong","year":"2021","unstructured":"Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219517.","journal-title":"Ann Rheum Dis"},{"key":"1822_CR13","unstructured":"OHDSI. OMOP Common Data Model. 2021. https:\/\/www.ohdsi.org\/data-standardization\/the-common-data-model\/. Accessed 7 Oct 2021."},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/CLEP.S323292","volume":"14","author":"D Prieto-Alhambra","year":"2022","unstructured":"Prieto-Alhambra D, Kostka K, Duarte-Salles T, et al. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. Clin Epidemiol. 2022;14:369\u201384. https:\/\/doi.org\/10.2147\/CLEP.S323292.","journal-title":"Clin Epidemiol."},{"key":"1822_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1038","volume":"373","author":"A Prats-Uribe","year":"2021","unstructured":"Prats-Uribe A, Sena AG, Lai LYH, et al. Use of repurposed and adjuvant drugs in hospital patients with COVID-19: multinational network cohort study. BMJ. 2021;373: n1038. https:\/\/doi.org\/10.1136\/bmj.n1038.","journal-title":"BMJ"},{"issue":"2","key":"1822_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2348252","volume":"41","author":"M Woodward","year":"1992","unstructured":"Woodward M. Formulae for sample size, power and minimum detectable relative risk in medical studies. J R Stat Soc D. 1992;41(2):185. https:\/\/doi.org\/10.2307\/2348252.","journal-title":"J R Stat Soc D."},{"issue":"6","key":"1822_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/ije\/dyy120","volume":"47","author":"Y Tian","year":"2018","unstructured":"Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005\u201314. https:\/\/doi.org\/10.1093\/ije\/dyy120.","journal-title":"Int J Epidemiol"},{"issue":"22","key":"1822_CR18","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1002\/sim.6977","volume":"35","author":"MJ Schuemie","year":"2016","unstructured":"Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35(22):3883\u20138. https:\/\/doi.org\/10.1002\/sim.6977.","journal-title":"Stat Med"},{"issue":"11","key":"1822_CR19","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1073\/pnas.1708282114","volume":"115","author":"MJ Schuemie","year":"2018","unstructured":"Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA. 2018;115(11):2571\u20137. https:\/\/doi.org\/10.1073\/pnas.1708282114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1822_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0962280210386207","volume":"21","author":"ML Petersen","year":"2012","unstructured":"Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ. Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res. 2012;21(1):31\u201354. https:\/\/doi.org\/10.1177\/0962280210386207.","journal-title":"Stat Methods Med Res"},{"issue":"7503","key":"1822_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92\u2013101. https:\/\/doi.org\/10.1038\/nature13479.","journal-title":"Nature"},{"issue":"7","key":"1822_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/89759","volume":"2","author":"BD Levy","year":"2001","unstructured":"Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612\u20139. https:\/\/doi.org\/10.1038\/89759.","journal-title":"Nat Immunol"},{"issue":"2","key":"1822_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375362","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97\u2013106. https:\/\/doi.org\/10.1159\/000375362.","journal-title":"Cardiology"},{"issue":"1","key":"1822_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40121-020-00363-w","volume":"10","author":"LC Abu Esba","year":"2021","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2021;10(1):253\u201368. https:\/\/doi.org\/10.1007\/s40121-020-00363-w.","journal-title":"Infect Dis Ther"},{"key":"1822_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00104-1","author":"TM Drake","year":"2021","unstructured":"Drake TM, Fairfield CJ, Pius R, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021. https:\/\/doi.org\/10.1016\/S2665-9913(21)00104-1.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"1822_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10787-021-00810-1","volume":"29","author":"CS Kow","year":"2021","unstructured":"Kow CS, Hasan SS. The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis. Inflammopharmacology. 2021;29(3):641\u20134. https:\/\/doi.org\/10.1007\/s10787-021-00810-1.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"1822_CR27","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1038\/s41598-021-84539-5","volume":"11","author":"J Park","year":"2021","unstructured":"Park J, Lee S-H, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19. Sci Rep. 2021;11(1):5087. https:\/\/doi.org\/10.1038\/s41598-021-84539-5.","journal-title":"Sci Rep"},{"key":"1822_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/TCRM.S79135","volume":"11","author":"N Moore","year":"2015","unstructured":"Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061\u201375. https:\/\/doi.org\/10.2147\/TCRM.S79135.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01822-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01822-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T07:30:28Z","timestamp":1676446228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01822-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01822-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"type":"print","value":"0012-6667"},{"type":"electronic","value":"1179-1950"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"27 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abbott contracted IQVIA for the conduct of this study. Prof. Prieto-Alhambra receives funding from the UK National Institute for Health Research in the form of a Senior Research Fellowship, and as part of the Oxford National Institute for Health Research Biomedical Research Centre. Prof. Giustino Varrassi had a contract with Abbott International, as a consultant for scientific projects. He is also a consultant for scientific projects with Domp\u00e9 Farmaceutici and Menarini Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have completed the ICMJE disclosure form at  and declare the following interests: Dani Prieto-Alhambra receives funding from the UK National Institute for Health Research in the form of a senior research fellowship and from the Oxford National Institute for Health Research Biomedical Research Centre. Junqing Xie receives the Clarendon Fund and Jardine scholarship (University of Oxford) to support her DPhil study. Dani Prieto-Alhambra\u2019s research group has received research grants from the European Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi and UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca and UCB Biopharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"These assets are de-identified, commercially available data products that could be purchased and licensed by any researcher. The collection and de-identification of these data assets is a process that is commercial intellectual property and not privileged to the data licensees and the co-authors on this study. Licensees of these data have signed data use agreements with the data vendors that detail the usage protocols for running retrospective research on these databases. All analyses performed in this study were in accordance with data use agreement terms as specified by the data owners. As these data are deemed commercial assets, there is no institutional review board applicable to the usage and dissemination of these result sets or required registration of the protocol with additional ethics oversight. Compliance with data use agreement terms, which stipulate how these data can be used and for what purpose, is sufficient for the licensing commercial entities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Patient-level data cannot be shared without approval from data custodians owing to local information governance and data protection regulations. Additional summary data, analytical code and detailed definitions of algorithms for identifying the events are available from the corresponding author on reasonable request to access the GitHub repository.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JQ-X, DP-A, SS, CT and GV conceived the study and contributed to the study design. JQ-X, JB and JA conducted the statistical analyses. JQ-X and DP-A interpreted the results and wrote the manuscript. All authors contributed to writing the manuscript, approved the final version and had final responsibility for the decision to submit for publication. The lead authors (JQ-X and JB) affirm that this manuscript is an honest, accurate and transparent account of the study being reported, that no important aspects of the study have been omitted and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. DP-A is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributors"}}]}}